Sodium Tetradecyl Sulfate Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of sodium tetradecyl sulfate during breastfeeding. Although sodium tetradecyl sulfate is unlikely to adversely affect the breastfed infant, international guidelines recommend that breastfeeding be withheld for 2 days after sclerotherapy.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Wong M, Parsi K, Myers K, et al. Sclerotherapy of lower limb veins: Indications, contraindications and treatment strategies to prevent complications - A consensus document of the International Union of Phlebology-2023. Phlebology. 2023;38:205–58. [PubMed: 36916540]
Substance Identification
Substance Name
CAS Registry Number
1191-50-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Sclerosing Solutions
Sclerotherapies
Surface-Active Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
